Brain neurotrophic factor (bdnf) and its diagnostic significance when measured in blood: analytical review

Shvaikovskaya, Anna A.; Zhanaeva, S. Ya.; Evsyukova, A.V.; Tikhonova, Maria A.; Danilenko, Konstantin V.; Aftanas, Lyubomir I.

doi:10.25789/ymj.2020.71.27

Cited by 9 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly important because BDNF and VEGF peripheral levels may be uncorrelated with brain levels because they are widely expressed in tissues outside the CNS. 48 , 49 Our findings, of robust association between serum levels of BDNF and VEGF measured in mid-life with later-life tau pathology on PET (indicating years of accumulating pathology) add to previous evidence by stressing the possible important role of these NTFs as valid and accessible blood biomarkers for AD. Our findings also provide additional clarification for the observed sex differences in AD vulnerability and may support previous evidence demonstrating the neuroprotective roles of estrogen, which include reduction of Aβ production, stimulation of Aβ degeneration, and prevention of tau hyperphosphorylation.…”

Section: Discussionsupporting

confidence: 70%

Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults

Weinstein,

Kojis,

Ghosh

et al. 2024

Neurology

View full text Add to dashboard Cite

Background and Objectives Neurotrophic factors (NTFs) play an important role in Alzheimer disease (AD) pathophysiology. Brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) are important NTFs. However, a direct link of BDNF and VEGF circulating levels with in vivo measures of amyloid-β (Aβ) and tau burden remains to be elucidated. We explored the relationship of BDNF and VEGF serum levels with future brain Aβ and tau pathology in a cohort of cognitively healthy, predominantly middle-aged adults and tested for possible effect modifications by sex and menopausal status. Methods This cross-sectional analysis was conducted using data from the Framingham Heart Study (FHS), a community-based cohort study. The study sample included cognitively healthy participants from the FHS Offspring and Third-generation cohorts. BDNF and VEGF were measured in the third-generation cohort during examination cycles 2 (2005–2008) and 1 (2002–2005), respectively, and in the offspring cohort during examination cycle 7 (1998–2001). Participants underwent 11 C-Pittsburgh compound B amyloid and 18 F-Flortaucipir tau–PET imaging (2015–2021). Linear regression models were used to assess the relationship of serum BDNF and VEGF levels with regional tau and global Aβ, adjusting for potential confounders. Interactions with sex and menopausal status were additionally tested. Results The sample included 414 individuals (mean age = 41 ± 9 years; 51% female). Continuous measures of BDNF and VEGF were associated with tau signal in the rhinal region after adjustment for potential confounders (β = −0.15 ± 0.06, p = 0.018 and β = −0.19 ± 0.09, p = 0.043, respectively). High BDNF (≥32,450 pg/mL) and VEGF (≥488 pg/mL) levels were significantly related to lower rhinal tau (β = −0.27 ± 0.11, p = 0.016 and β = −0.40 ± 0.14, p = 0.004, respectively) and inferior temporal tau (β = −0.24 ± 0.11, p = 0.028 and β = −0.26 ± 0.13, p = 0.049, respectively). The BDNF-rhinal tau association was observed only among male individuals. Overall, BDNF and VEGF were not associated with global amyloid; however, high VEGF levels were associated with lower amyloid burden in postmenopausal women (β = −1.96 ± 0.70, p = 0.013, per 1 pg/mL). Discussion This study demonstrates a robust association between BDNF and VEGF serum levels with in vivo measures of tau almost 2 decades later. These findings add to mounting evidence from preclinical studies suggesting a role of NTFs as valuable blood biomarkers for AD risk prediction.

show abstract

Section: Discussionsupporting

confidence: 70%

Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults

Weinstein,

Kojis,

Ghosh

et al. 2024

Neurology

View full text Add to dashboard Cite

show abstract

“…Despite the fact that blood BDNF concentration reflects brain-tissue BDNF levels in some animals ( Klein et al, 2011 ), the human data in this field are scarce. Notably, in humans, BDNF is widely expressed outside of the central nervous system, namely, in white blood cells, platelets, vascular endothelium, smooth muscles, and other peripheral tissues ( Shvaikovskaya et al, 2020 ). Thus, its serum levels are likely to be influenced by peripheral sources rather than central BDNF levels.…”

Section: Discussionmentioning

confidence: 99%

Brain but not serum BDNF levels are associated with structural alterations in the hippocampal regions in patients with drug-resistant mesial temporal lobe epilepsy

Filimonova,

Pashkov,

Moysak

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

Mesial temporal lobe epilepsy is the most common type of focal epilepsy, imposing a significant burden on the health care system worldwide. Approximately one-third of patients with this disease who do not adequately respond to pharmacotherapy are considered drug-resistant subjects. Despite having some clues of how such epileptic activity and resistance to therapy emerge, coming mainly from preclinical models, we still witness a scarcity of human data. To narrow this gap, in this study, we aimed to estimate the relationship between hippocampal and serum levels of brain-derived neurotrophic factor (BDNF), one of the main and most widely studied neurotrophins, and hippocampal subfield volumes in patients with drug-resistant mesial temporal epilepsy undergoing neurosurgical treatment. We found that hippocampal (but not serum) BDNF levels were negatively correlated with the contralateral volumes of the CA1 and CA4 subfields, presubiculum, subiculum, dentate gyrus, and molecular layer of the hippocampus. Taken together, these findings are generally in accordance with existing data, arguing for a proepileptic nature of BDNF effects in the hippocampus and related brain structures.

show abstract

“…A significant part of them leads to disruption of the BBB function. Penetrating from the bloodstream into the brain, these proteins cause destructive processes in neurons, as well as the development of nonspecific acute-phase reactions such as edema or inflammation [11].…”

Section: Resultsmentioning

confidence: 99%

Altered serum levels of neuronal proteins and antibodies to them in occupational diseases of the nervous system

Bodienkova,

Boklazhenko

2024

BIOMED KHIM

View full text Add to dashboard Cite

Aclinical and immunological examination of men with occupational pathology, including vibration disease (VD), occupational sensorineural hearing loss (SHL), and chronic mercury intoxication (CMI), was carried out. The comparison group consisted of men comparable in age and total work experience. Serum concentrations of neurotrophins (S100β, MBP, BDNF) and antibodies (ABs) to S100β and MBP proteins were determined by enzyme-linked immunosorbent assay. An increase in the level of the S100β protein was shown in CMI, VD, and a tendency for its increase was found in SHL. In parallel, an increase in AB to the S100β protein in VD and SHL and a decrease in AB in CMI were noted. A comparative assessment of MBP levels indicated a pronounced increase in its serum concentrations in patients with CMI and VD versus the comparison group. At the same time, an increase in the level of serum ABs to MBP in individuals with VD and SHL, and a decrease in patients with CMI were noted. In patients with CMI, a significant decrease in the BDNF concentration was found, while in SHL and VD, no statistically significant differences were found in comparison with the comparison group. The results obtained confirm importance of assessing serum concentrations of neurotrophic proteins and ABs to them in the case of occupational damage to the nervous system caused by exposure to physical and chemical factors.

show abstract

Brain neurotrophic factor (bdnf) and its diagnostic significance when measured in blood: analytical review

Cited by 9 publications

References 0 publications

Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults

Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults

Brain but not serum BDNF levels are associated with structural alterations in the hippocampal regions in patients with drug-resistant mesial temporal lobe epilepsy

Altered serum levels of neuronal proteins and antibodies to them in occupational diseases of the nervous system

Contact Info

Product

Resources

About